https://www.selleckchem.com/pr....oducts/blebbistatin.
A face-to-face consensus meeting with key stakeholders will be conducted to finish a final COS and recommend measurement instruments for each outcome. RESULTS We will develop a COS that should be reported in future clinical trials to evaluate the effectiveness of PI treatment. DISCUSSION The COS will follow current guidance to develop a high-quality COS in the field of PI treatment to reduce heterogeneity in trial reporting, facilitate valid comparisons of new therapies, and improve the quality of clinical trials.BACKGROUND Lumbar
Like
Comment
Share
